Cardiology

Left atrial appendage occlusion may reduce ischaemic stroke risk in AF

Roshini Claire Anthony, Yesterday

Left atrial appendage occlusion (LAAO) added to usual care led to a reduction in ischaemic stroke or non-cerebral systemic embolism following cardiac surgery among patients with atrial fibrillation (AF), according to results of the LAAOS* III trial.

Atorvastatin: Is there evidence of benefit in COVID-19?

Elvira Manzano, Yesterday

Treatment with the HMG-CoA reductase inhibitor atorvastatin in critically ill patients with COVID-19 did not significantly reduce the primary composite outcome of venous or arterial thrombosis risk, treatment with extracorporeal membrane oxygenation (ECMO), or mortality vs placebo in the INSPIRATION-S study presented at ACC.21.

Minority of SIHD patients undergoing PCI meet ISCHEMIA trial criteria

Roshini Claire Anthony, 3 days ago

Only a small fraction of patients with stable ischaemic heart disease (SIHD) who undergo percutaneous coronary intervention (PCI) in the US meet the inclusion criteria of the ISCHEMIA* trial, according to results of a study presented at SCAI 2021.

Original New Drug Application Approvals by US FDA (01 - 15 June 2021)

3 days ago

New drug applications approved by US FDA as of 01-15 June 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Trimetazidine new formulation redefining angina control in daily practice

12 Mar 2021

Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.

Empagliflozin not just another SGLT2i: Cardio-renal benefits extend to HF with or without diabetes

Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Empagliflozin: Another SGLT-2i in HFrEF armamentarium

Roshini Claire Anthony, 05 Nov 2020

Adding empagliflozin to recommended therapy in patients with heart failure with reduced ejection fraction (HFrEF) reduced the risk of HF hospitalization and slowed renal function decline, the EMPEROR-Reduced* trial showed.

Empagliflozin advancing on all fronts: Readying for the future with EMPEROR

11 Aug 2020

In this final issue of our series, join us as we look into the upcoming results of the pivotal EMPEROR trials, which will investigate the use of empagliflozin in patients with either preserved or reduced ejection fraction heart failure, with or without type 2 diabetes. Understand why heart failure has such a high clinical burden, and the great unmet need in providing solutions for it.

Empagliflozin near to us: Insights from its use in Asians

09 Jul 2020

In this fourth issue, join us as we discover the unique biology Asians have with respect to diabetes. Take a closer look at trials evaluating whether empagliflozin’s cardiovascular and renal benefits – as analysed in Asians – are consistent with the overall trial population, and how it addresses unmet needs.

Left atrial appendage occlusion may reduce ischaemic stroke risk in AF

Roshini Claire Anthony, 17 Jun 2021

Atorvastatin: Is there evidence of benefit in COVID-19?

Elvira Manzano, 17 Jun 2021

Minority of SIHD patients undergoing PCI meet ISCHEMIA trial criteria

Roshini Claire Anthony, 15 Jun 2021

Finerenone reduces risk of new-onset AF in patients with CKD, T2D

Elaine Soliven, 12 Jun 2021

Treatment with finerenone led to a significantly reduced risk of new-onset atrial fibrillation (AF) in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), according to the FIDELIO-DKD* trial presented at the ACC.21 Virtual Meeting.

Clopidogrel bests aspirin as maintenance monotherapy post-PCI

Pearl Toh, 10 Jun 2021

Long-term maintenance monotherapy with clopidogrel is superior to aspirin in reducing the risk of both ischaemic and major bleeding events in patients who had successfully undergone 6–18 months of DAPT* without any clinical event following a percutaneous coronary intervention (PCI), the head-to-head HOST-EXAM** trial has shown.

Pirfenidone PIROUETTES from treating lung to heart scarring

Audrey Abella, 10 Jun 2021

The oral antifibrotic agent pirfenidone – a drug currently approved for the treatment of idiopathic lung fibrosis – significantly reduced scarring of the heart muscle in individuals with chronic heart failure with preserved ejection fraction (HFpEF) and myocardial fibrosis, according to findings from the early-phase PIROUETTE trial presented at ACC.21.

Renal denervation: An adjunct for treating drug-resistant hypertension?

Audrey Abella, 07 Jun 2021

Ultrasound renal denervation (RDN) offers a blood-pressure (BP) lowering benefit for individuals with triple drug-resistant hypertension compared with a sham procedure, according to the RADIANCE-HTN TRIO trial presented at ACC.21.